In any case, at least for oral DNG therapy, KRAS status may be a biomarker of treatment efficacy, and testing a needle biopsy of an adenomyosis lesion for KRAS mutation and/or PR expression might be a valuable diagnostic option. This evidence concerns the gene KRAS and adenomyosis.